Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20930446 | 0.74 | JAK1 (0.51) | JAK1 | |
| SCHEMBL20930670 | 0.74 | JAK1 (0.51) | JAK1ADORA2AADORA1 | |
| SCHEMBL20918455 | 0.73 | JAK1 (0.56) | JAK1ABL1 | |
| SCHEMBL20918453 | 0.73 | JAK1 (0.48) | JAK1ABL1 | |
| SCHEMBL20496646 | 0.72 | JAK2 (0.65) | JAK1GSK3B | |
| SCHEMBL20930854 | 0.72 | JAK1 (0.45) | JAK1ABL1 | |
| SCHEMBL20918015 | 0.72 | JAK1 (0.71) | JAK1ABL1 | |
| SCHEMBL30356056 | 0.72 | JAK1 (0.71) | JAK1ABL1 | |
| SCHEMBL20917955 | 0.72 | JAK1 (0.71) | JAK1 | |
| SCHEMBL20918119 | 0.71 | JAK1 (0.74) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | claimed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | disclosed |
| EP-3697787-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | HK inno.N Corporation (KR) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019078619-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | CJ HEALTHCARE CORPORATION (KR) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885ADORA2A 3930/4885ADORA1 4351/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885ADORA2A 3930/4885ADORA1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.